Physician profile
Phani Ashok Attaluri
NPI 1417066499
$957,071.77
in general payments reported to CMS, 2019-2025
35 companies · $234K in 2025
The $234K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $28K · 2021: $34K · 2022: $88K · 2023: $188K · 2024: $260K · 2025: $234K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $599K · Travel and Lodging: $43K · Consulting Fee: $25K · Food and Beverage: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,275 · Education: $42.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $599,026.66 |
| Travel and Lodging | $43,407.28 |
| Consulting Fee | $24,625.50 |
| Food and Beverage | $10,177.82 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,275.00 |
| Education | $42.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $329,036.21 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $317,937.37 | 2022-2025 | Dupixent |
| Abbvie INC. | $107,959.91 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97,876.14 | 2019-2025 | Trulance, Xifaxan, Uceris |
| Merck Sharp & Dohme LLC | $26,068.89 | 2019-2023 | Dificid, Zinplava |
| Ardelyx, INC. | $15,914.16 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $15,384.27 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $10,166.42 | 2020-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $9,273.25 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $8,974.44 | 2019-2025 | |
| Allergan, INC. | $6,800.99 | 2019-2020 | |
| Celgene Corporation | $3,272.19 | 2022-2024 | Zeposia |
| Alfasigma USA, INC. | $2,028.68 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,976.45 | 2022 | |
| Boston Scientific Corporation | $1,233.72 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $927.69 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Covidien Lp | $534.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $525.00 | 2020 | |
| Mallinckrodt Hospital Products INC. | $202.13 | 2025 | Terlivaz |
| Medtronic, INC. | $175.90 | 2023 | Endoflip |
| Nestle Healthcare Nutrition INC. | $122.67 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $113.56 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $113.55 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $90.93 | 2019-2025 | Sucraid |
| Lilly USA, LLC | $81.59 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $68.56 | 2024-2025 | Vegzelma, Zymfentra |
| Madrigal Pharmaceuticals | $43.44 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $30.95 | 2019-2023 | |
| Romark Laboratories, Lc | $29.26 | 2019 | |
| Braintree Laboratories, INC. | $23.53 | 2019 | |
| Shionogi INC | $22.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $22.25 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $14.67 | 2020 | |
| Daiichi Sankyo INC. | $14.14 | 2019 | |
| Shire North American Group INC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phani Ashok Attaluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.